About MEMS   |   Council   |   Members Centre   |   Membership   |   Contact Us   |   Home
  Member Login     username:     password:           Forgot your password?
  Home » Announcements & Updates » 
President’s Message
The Endocrine Directory
Calendar of Events
Announcements & Updates
Breaking News & Reports
In the Press
Disease Areas
Healthy Lifestyle
Research Programs
Photo & Video Gallery
Useful Links
Disease Management
arrow Insulin analogues and cancer: a possible link that needs further investigation
Diabetologia, the journal of the European Association for the Study of Diabetes (EASD), has just published a series of research papers that have examined a possible link between one of the insulin analogues and the risk of being diagnosed with cancer. This report provides a summary of the information available.
»

arrow Statement from the Malaysian Endocrine and Metabolic Society (MEMS) on the News of the Possible Link between Insulin Glargine (Lantus) and Cancers
Three out of four of the observational studies showed possible link while the fourth did not. A separate randomised control trial conducted by Sanofi-Aventis, the manufacturer of glargine to examine the effect of the drug on diabetes-related eye disease did not show any link between the drug and cancers. As such until further prospective study specifically examining the question is performed, the Malaysian Endocrine and Metabolic Society (MEMS) would like to advise patients and the general public not to overact to this news. There is no conclusive evidence to suggest that glargine or any other insulin for that matter cause cancers.
»

arrow Journal of the Asean Federation of Endocrine Societies
Proceedings of the First Malaysian Endocrine And Metabolic Society Annual Congress,
Penang, Malaysia. 28th-31st May 2009.
»

arrow Summary from the authors of the study in NEJM
A strategy of prompt coronary revascularization in patients who had been treated with intensive medical therapy for diabetes and stable ischemic disease did not significantly reduce the rate of death from any cause or of major cardiovascular events.

»

arrow MAC 2009 - programme book
Date: 28th - 31th May 2009
Venue: Parkroyal Hotel, Penang
Theme: Taking the mystery out of endocrinology
»

arrow Report from American Diabetes Association Annual Scientific Meeting 2009, New Orleans, LA, USA
Primary end points : Rosiglitazone is non inferior to metformin or sulphonylurea in terms of CV outcomes. There were as expected significantly more heart failure and unusual fractures.
»


| | | |
© Copyright Malaysian Endocrine & Metabolic Society (MEMS)   2009 - 2016    All rights reserved.
designed & maintained: mobition